1.1. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.2.2. Irwin DE, Mungapen L, Milsom I et al. The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2009; 103 (2): 202-9.3.3. Michel MC, Chapple CR. Basic mechanisms of urgency: roles and benefits of pharmacotherapy. World J Urol 2009; 27: 705-9.4.4. Andersson K.-E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 2011; 59: 377-86.5.5. Lucas MG, Bosch JLHR, Cruz FR et al. Guidelines on Urinary Incontinence. European Association of Urology, 2012.6.6. Abrams P, Cardozo L, Khoury S, Wein A (editors). Incontinence. 4th International Consultation on Incontinence, Paris, July 5-8, 2008. Paris: Health Publication Ltd, 2009.7.7. Cardozo L. Systematic review of overactive bladder therapy in females. Can Urol Assoc J 2011; 5 (Suppl. 2): S139-S142.8.8. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol 2000; 129: 416-9.9.9. Malone-Lee JG, Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 2009; 103: 931-7.10.10. Hartmann KE, McPheeters ML, Biller DH et al. Treatment of Overactive Bladder in Women. Evidence Report/Technology Assessment; 187.11.11. Shamliyan T, Wyman JF, Ramakrishnan R et al. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med 2012; 156 (12): 861-74.12.12. Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012: doi: 10.1111/j.1464-410X.2012.11023.x13.13. Geyer J, Gavrilova O, Petzinger E. The role of p-glycoproteine in limiting brain penetration of the peripherally acting of anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos 2009; 37: 1371-4.14.14. Sand PK, Rovner ES, Watanabe JH, Oefelein MG. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging 2011; 28: 151-60.15.15. Chancellor MB, Oefelein MG, Vasavada S. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with oncedaily administration of trospium chloride extended release. Neurourol Urodyn 2010; 29: 551-4.16.16. Fuertes ME et al. Clinical trial to evaluate trospium chloride (Uraplex) effectiveness and tolerance in patients with detrusor instability incontinence and its impact on quality of life. Arch Esp Urol 2000; 53 (2): 125-36.17.17. Sand PK, Dmochowski RR, Zinner NR et al. Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20 (12): 1431-8.18.18. Школьников М.Е. Спазмекс в лечении гиперактивного мочевого пузыря. Отечественный опыт применения. Урология. 2009; 6: 77-82.19.19. Школьников М.Е., Мазо Е.Б., Кривобородов Г.Г. и др. Троспия хлорид в комплексном лечении женщин с пролапсом гениталий и гиперактивным мочевым пузырем. Урология. 2008: 16-9.20.20. Kaya C et al. The efficacy of trospium chloride in women with an overactive bladder. Marmara Med J 2008; 21 (2); 127-32.21.21. Данилова Т.И., Данилов В.В., Лучинский С.А., Васильченко А.В. Сексуальные дисфункции у женщин с гиперактивным мочевым пузырем и их коррекция м-холинолитиком спазмексом. Урология. 2010; 30-4.22.22. Rovner ES, Wein AJ. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002; 41: 6-14.23.23. Wiedemann A, Kusche W, Neumeister C. Flexible Dosing of Trospium Chloride for the Treatment of OAB - Results of a Non-Interventional Study in 4,092 Patients. Open Clin Trials J 2011; 3: 1-5.24.24. Kessler TM, Bachmann LM, Minder C et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 2011; 6 (2): e16718.25.25. Bödeker RH, Madersbacher H, Neumeister C, Zellner M. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol 2010; 10: 15.26.26. Wiedemann A, Neumann G, Neumeister C et al. Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Non-Interventional Trial Showing Use of Flexible Dosing. UroToday Int J 2009; 2 (2).